Deadline approaching: Bronstein, Gewirtz & Grossman LLC reminds applicants of APLT deadline

A class action lawsuit has recently been initiated against Applied Therapeutics, Inc. and some of its executives for alleged violations of federal securities laws. The lawsuit has been filed on behalf of investors who purchased shares of Applied Therapeutics between November 7, 2019, and January 4, 2021.

The complaint alleges that Applied Therapeutics made false and misleading statements regarding the efficacy of its lead drug candidate, AT-007. The company claimed that AT-007 was showing positive results in its clinical trials and had the potential to receive accelerated approval from the U.S. Food and Drug Administration (FDA). However, it is alleged that Applied Therapeutics failed to disclose that there were issues with the drug’s data, which could impact its chances of FDA approval.

As a result of these alleged misrepresentations, Applied Therapeutics’ stock price surged to a high of $87.52 per share on January 6, 2020. However, when the truth about the drug’s efficacy concerns came to light, the stock plummeted to $7.70 per share on January 4, 2021. This drastic drop in stock price caused significant financial losses for investors who had purchased shares of Applied Therapeutics during the class period.

The lawsuit seeks to recover damages for investors who suffered losses as a result of investing in Applied Therapeutics during the specified time frame. The plaintiff is represented by a well-known securities litigation firm that specializes in representing investors in class action lawsuits against companies that have allegedly engaged in securities fraud.

Investors who purchased shares of Applied Therapeutics during the class period and suffered financial losses may be eligible to join the class action lawsuit. It is important for investors to be aware of their rights and options in such cases, as these lawsuits aim to hold companies accountable for any alleged wrongdoing that may have caused harm to investors.

Securities class action lawsuits are a common tool used by investors to seek recourse for losses incurred as a result of securities fraud committed by companies. These lawsuits help to protect investors by holding companies accountable for their actions and providing a means for affected investors to seek compensation for their losses.

In conclusion, the class action lawsuit against Applied Therapeutics highlights the importance of transparency and honesty in the pharmaceutical industry. Investors should always conduct thorough due diligence before investing in any company, especially in the biotech and pharmaceutical sectors where companies often face regulatory scrutiny and market volatility. If you believe you have been affected by the alleged misconduct of Applied Therapeutics, it is advisable to seek legal counsel and explore your options for potential recovery of losses.